Profile data is unavailable for this security.
About the company
Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.
- Revenue in USD (TTM)640.44m
- Net income in USD-800.71m
- Incorporated2015
- Employees2.30k
- LocationTempus AI Inc600 West Chicago Avenue, Suite 510CHICAGO 60654United StatesUSA
- Fax+1 (302) 655-5049
- Websitehttps://www.tempus.com/
More ▼
Mergers & acquisitions
| Acquired company | TEM:NSQ since announced | Transaction value |
|---|---|---|
| Ambry Genetics Corp | 47.72% | 600.00m |
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exact Sciences Corp | 2.69bn | -214.04m | 9.50bn | 6.50k | -- | 2.96 | 5,211.17 | 3.53 | -1.17 | -1.17 | 14.70 | 17.35 | 0.4089 | 5.40 | 11.60 | 414,204.30 | -3.25 | -9.71 | -3.58 | -10.60 | 72.96 | 74.10 | -7.95 | -28.21 | 1.93 | -- | 0.4459 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| Revolution Medicines Inc | 742.00k | -567.06m | 10.19bn | 490.00 | -- | 6.49 | -- | 13,738.67 | -3.59 | -3.59 | 0.0047 | 9.34 | 0.0005 | -- | 4.80 | 1,962.96 | -41.28 | -29.76 | -44.46 | -32.59 | -- | -- | -76,423.31 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Exelixis Inc | 2.08bn | 466.92m | 10.34bn | 1.31k | 23.06 | 4.55 | 20.90 | 4.96 | 1.57 | 1.57 | 6.92 | 7.96 | 0.7012 | 3.39 | 8.04 | 1,589,006.00 | 15.73 | 8.86 | 18.08 | 9.91 | 96.25 | 96.30 | 22.43 | 15.43 | 3.88 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Sarepta Therapeutics Inc | 1.64bn | 121.85m | 11.26bn | 1.31k | 96.90 | 9.22 | 70.14 | 6.86 | 1.22 | 1.22 | 16.30 | 12.79 | 0.489 | 0.5703 | 4.35 | 1,248,362.00 | 3.63 | -21.63 | 4.38 | -25.75 | 85.92 | 86.65 | 7.43 | -77.05 | 3.03 | -- | 0.5013 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.06bn | 413.08m | 11.29bn | 20.00k | 27.55 | 2.98 | 14.69 | 2.78 | 8.01 | 8.01 | 78.63 | 73.97 | 0.5203 | 8.27 | 5.23 | 203,045.80 | 5.48 | 6.46 | 6.33 | 7.62 | 35.93 | 36.99 | 10.54 | 11.58 | 1.14 | 4.96 | 0.3784 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
| Medpace Holdings Inc | 2.07bn | 365.57m | 11.30bn | 5.90k | 31.84 | 12.79 | 28.65 | 5.46 | 11.42 | 11.42 | 64.70 | 28.42 | 1.16 | -- | 6.85 | 350,994.30 | 20.48 | 13.94 | 43.51 | 23.18 | 29.69 | 28.84 | 17.66 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| BIO-TECHNE Corp | 1.17bn | 150.68m | 11.87bn | 3.10k | 79.44 | 5.55 | 45.29 | 10.13 | 0.9402 | 0.9402 | 7.29 | 13.46 | 0.4267 | 2.15 | 5.47 | 377,930.00 | 5.49 | 9.42 | 5.77 | 10.04 | 65.93 | 67.29 | 12.86 | 21.41 | 3.26 | 18.07 | 0.123 | 22.79 | 1.97 | 10.17 | -41.07 | 11.86 | 19.87 | 0.00 |
| Tempus AI Inc | 640.44m | -800.71m | 12.22bn | 2.30k | -- | 224.39 | -- | 19.08 | -8.29 | -8.29 | 4.44 | 0.3459 | -- | -- | -- | -- | -- | -- | -- | -- | 53.18 | -- | -116.06 | -- | 2.55 | -14.95 | 0.891 | -- | 65.85 | -- | 20.35 | -- | -- | -- |
| Insmed Inc | 342.96m | -864.29m | 12.85bn | 912.00 | -- | 26.57 | -- | 37.46 | -5.56 | -5.56 | 2.21 | 2.70 | 0.2031 | 0.8848 | 8.81 | 376,050.40 | -51.17 | -40.96 | -59.16 | -46.88 | 77.25 | 77.99 | -252.01 | -212.92 | 5.99 | -18.41 | 0.6702 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
| Neurocrine Biosciences, Inc. | 2.24bn | 385.90m | 12.88bn | 1.70k | 34.06 | 4.73 | 31.28 | 5.74 | 3.73 | 3.73 | 21.67 | 26.87 | 0.7027 | 0.8901 | 4.99 | 1,602,000.00 | 12.09 | 9.77 | 14.67 | 12.19 | 98.52 | 98.51 | 17.21 | 14.79 | 4.26 | 10.28 | 0.00 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
| Vaxcyte Inc | 0.00 | -507.65m | 12.92bn | 254.00 | -- | 3.77 | -- | -- | -4.55 | -4.55 | 0.00 | 27.47 | 0.00 | -- | -- | 0.00 | -20.08 | -34.22 | -20.95 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
| Summit Therapeutics Inc | 0.00 | -196.68m | 16.05bn | 105.00 | -- | 36.64 | -- | -- | -0.2768 | -0.2768 | 0.00 | 0.5941 | 0.00 | -- | -- | 0.00 | -54.53 | -77.32 | -71.71 | -86.35 | -- | -- | -- | -20,989.46 | -- | -- | 0.053 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Moderna Inc | 5.08bn | -2.22bn | 16.43bn | 5.60k | -- | 1.38 | -- | 3.23 | -5.81 | -5.81 | 13.14 | 30.98 | 0.2883 | 2.44 | 2.96 | 907,321.40 | -12.62 | 20.95 | -15.52 | 29.51 | 78.43 | -- | -43.77 | 32.10 | 4.20 | -- | 0.0521 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
Data as of Nov 12 2024. Currency figures normalised to Tempus AI Inc's reporting currency: US Dollar USD
9.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Associates, Inc. (IM)as of 30 Jun 2024 | 5.23m | 3.50% |
| ARK Investment Management LLCas of 30 Sep 2024 | 2.38m | 1.59% |
| Nikko Asset Management Americas, Inc.as of 30 Sep 2024 | 1.22m | 0.82% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 1.05m | 0.70% |
| AllianceBernstein LPas of 30 Jun 2024 | 967.27k | 0.65% |
| Lingotto Investment Management LLPas of 30 Jun 2024 | 933.86k | 0.63% |
| Massachusetts Financial Services Co.as of 30 Jun 2024 | 807.04k | 0.54% |
| Franklin Advisers, Inc.as of 30 Jun 2024 | 802.92k | 0.54% |
| BAMCO, Inc.as of 30 Jun 2024 | 784.40k | 0.53% |
| Columbia Management Investment Advisers LLCas of 30 Jun 2024 | 682.40k | 0.46% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
